SCHEMBL3652149

SCHEMBL3652149

Cc1cc(F)ccc1N1CCN(S(=O)(=O)c2cccc3ccccc23)CC1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 8/20 0.47
MAPT P10636 3/20 0.47
TP53 P04637 1/20 0.47
GPR183 P32249 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
FABP1 P07148 1/20 0.42
TSHR P16473 1/20 0.41
EPHX2 P34913 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR6 P50406 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3653913 0.88 NR1D1 (0.52) CNR1MAPTTP53GPR183MEN1
SCHEMBL3643820 0.87 HTR2A (0.46) MAPTTP53FABP1EPHX2HTR2A
SCHEMBL3655511 0.85 FABP1 (0.59) MAPTTP53FABP1TSHRHTR2A
SCHEMBL3693526 0.83 MAPT (0.49) CNR1MAPTTP53GPR183MEN1
SCHEMBL3689998 0.82 MAPT (0.48) CNR1MAPTTP53GPR183TSHR
SCHEMBL3692614 0.82 MAPT (0.47) CNR1MAPTTP53GPR183ALDH1A1
SCHEMBL3652616 0.80 GPR183 (0.46) MAPTGPR183MEN1KMT2ATSHR
SCHEMBL3704123 0.79 HSD11B1 (0.59) CNR1MAPTFABP1TSHR
SCHEMBL3649848 0.78 LMNA (0.37) MAPTTP53MEN1KMT2AEPHX2
SCHEMBL4214246 0.76 SLC6A9 (0.48) MEN1KMT2ATSHRALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188266-B1 Novel piperazine amide derivatives HOFFMANN LA ROCHE (CH) 2012-10-17 EP disclosed
US-8288541-B2 Piperazine amide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-10-16 US disclosed
EP-2188266-A2 NOVEL PIPERAZINE AMIDE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-26 EP disclosed
WO-2009021868-A2 NOVEL PIPERAZINE AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-02-19 WO disclosed
US-20090048264-A1 PIPERAZINE AMIDE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048264-A1 PIPERAZINE AMIDE DERIVATIVES NR1H2, NR1H3, NR1I2 CNR1 55/4885MAPT 4226/4885TP53 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.